Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 16, 2011, Pages 2493-2503

  Kaur, Antarpreet ^a   Dasanu, Constantin A ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

esophageal cancer; gastric cancer; HER2 pathway; lapatinib; monoclonal antibodies (mAbs); trastuzumab; tyrosine kinase inhibitors (TKIs)

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; AFATINIB; ANTINEOPLASTIC AGENT; CAPECITABINE; CARENTINIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERTUMAXOMAB; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; LAPATINIB; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; TAK 285; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL; CANCER STAGING; CARDIOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CYTOPENIA; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GLIOMA; HEAD AND NECK CANCER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; RASH; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; HUMANS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 80054074923     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.605354     Document Type: Review

References (80)

1. Alberts SR, Cervantes A, Van De Velde CJ, et al. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14(Suppl 2):31-6
2. Sedlacek HH. Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000;59:435-76 (Pubitemid 30213854)
3. Wells A. EGFR receptor. Int J Biochem Cell Biol 1999;31:637-43
4. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004;9:58-67 (Pubitemid 38134014)
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37
6. Jones JT, Akita RW, Sliwkowski M. Binding specificities and affinities of egf domains of ErbB receptors. FEBS Lett 1999;447:227-31 (Pubitemid 29146091)
7. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67 (Pubitemid 26151185)
8. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999;96:4995-5000 (Pubitemid 29214524)
9. Janmaat ML, Kruyt FA, Rodriguez JA, et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26 (Pubitemid 36687658)
10. Kraus AC, Ferber I, Bachmann SO, et al. In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002;21:8683-95 (Pubitemid 36132389)
11. Moscatello DK, Holgado-Madruga M, Emlet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998;273:200-6 (Pubitemid 28042194)
12. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and cerbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25
13. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-7 (Pubitemid 36827302)
14. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91:1532-42 (Pubitemid 39486359)
15. Becker JC, Miller-Tidow C, Serve H, et al. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 2006;12:3297-305 (Pubitemid 43933772)
16. Ghaderi A, Vasei M, Maleck-Hosseini SA, et al. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res 2002;8:252-6 (Pubitemid 36249604)
17. Kimura M, Tsuda H, Morita D, et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 2004;445:255-62 (Pubitemid 39286893)
18. Kawaguchi Y, Kono K, Mimura K, et al. Targeting EGFR and HER-2 with cetuximab-and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007;97:494-501 (Pubitemid 47258449)
19. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006;118:1173-80 (Pubitemid 43185604)
20. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibodydependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:4849-904
21. Reichelt U, Duesedau P, Tsourlakis MCH, et al. Frequent Homogenous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-9 (Pubitemid 44967957)
22. Hayashi Y, Widjono YW, Ohta K, et al. Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues. Pathol Int 1994;44:124-30 (Pubitemid 24072143)
23. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors(EGFR, ERB B2, ERB B3) on colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105-15 (Pubitemid 30114656)
24. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904 (Pubitemid 38993773)
25. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspective for targeted therapies. Lung Cancer 2003;41(Suppl 1):S29-42 (Pubitemid 36818993)
26. Hirsch FR, Langer CJ. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol 2004;31(1-S):75-82 (Pubitemid 38241024)
27. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44 (Pubitemid 35340719)
28. Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:1957-62
29. Wester K, Sjostrom A, de la Torre M, et al. HER-2-a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002;41:282-8 (Pubitemid 34833053)
30. Lae M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010;21:815-19
31. Safran H, Steinhoff M, Mangray S, et al. Overexpression of HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2002;24:496-9 (Pubitemid 32959109)
32. Goebel SU, Iwamoto M, Raffeld M, et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 2002;62:3702-10 (Pubitemid 34728850)
33. Steffensen KD, Waldstorm M, Anderson RF, et al. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol 2008;33:195-204
34. Seki A, Yoshinouchi M, Seki N, et al. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol 2000;17:103-6
35. Fukushige S, Mastubara K, Yoshida M, et al. Localization of a novel c-erb related gene, c-erbB2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955-8 (Pubitemid 16135959)
36. Yonemura Y, Ohoyama S, Kimura H, et al. The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma. Cancer 1991;67:2523-8
37. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33
38. Bang Y, Chuang J, Xu F, et al. Pathological features of advanced gastric cancer: relationship to human epidermal growth factor receptor 2 (HER2) positivity in global screening program ToGA trial. J Clin Oncol 2009;27(Suppl):4556
39. Roh JK, Paik S, Chun HC, et al. Overexpression of erbB-2 protein in gastric adenocarcinoma-a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. Jpn J Cancer Chemother 1992;19(8 Suppl):1207-19
40. Yonemura Y, Ninomiya I, Ohoyama S, et al. Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer. Oncology 1992;49:363-7
41. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993;72:3179-84 (Pubitemid 23356757)
42. Lee HR, Kim JH, Uhm HD, et al. Overexpression of c-erbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 1996;53:192-7 (Pubitemid 26131941)
43. Shun CT, Wu MS, Lin JT, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 1997;44:604-9
44. Wu MS, Shun CT, Wang HP, et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage and Helicobacter pylori infection. Gastroenterology 1997;112:1457-65
45. Allgayer H, Babic R, Gruetzner KU, et al. CerbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000;18:2201-9 (Pubitemid 30350211)
46. Lee KE, Lee HJ, Kim YH, et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003;33:173-9 (Pubitemid 43102860)
47. Park DI, Yun JW, Park JH, et al. Her2/ neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-9 (Pubitemid 44315804)
48. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805 (Pubitemid 351724903)
49. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogeneous in gastric cancer. Hum Pathol 2010;40:769-77
50. Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of ER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-18
51. Tateishi M, Toda T, Minamisono Y, et al. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992;49:209-12
52. Sasano H, Date F, Imatani A, et al. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993;24:584-9 (Pubitemid 23162224)
53. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase 2alfa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8 (Pubitemid 40309309)
54. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999;85:1894-902 (Pubitemid 29202761)
55. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase 2-alfa associated with ErbB-2 amplification and affect sensitivity to topoisomerase 2 inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47 (Pubitemid 30626942)
56. Mizutani T, Onda M, Tokanaga A, et al. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993;72:2083-8 (Pubitemid 23280130)
57. Gravalos C, Marquez A, Garcia-Carbonero R, et al. Correlation between HER2/neu overexpresion/ amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study [abstract 89]. 2007 Gastrointestinal Cancer Symposium, Jan 19-21, 2007, Orlando, FL
58. Bang YJ, Van Custem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010;376:687-97
59. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9
60. Carter P, Presta L, Gorman CM, et al. Humanization of anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9
61. Cameron D, Casey M, Press M, et al. A phase 3 randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysis. Breast Cancer Res Treat 2008;112:533-43
62. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007;369:29-36 (Pubitemid 46039831)
63. Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm 2000;57:2063-76
64. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31:459-67 (Pubitemid 351695459)
65. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: Breast Cancer International Research Group 006 (BCIRG 006) Study [abstract 29]. San Antonio Breast Cancer Symposium (SABCS) San Antonio, TX,Dec 2009
66. Tan-Chui E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-19 (Pubitemid 46657378)
67. Morrow PK, Zambrana F, Esteva FJ, et al. Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res 2009;11(4):207
68. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer 2010;46:1949-59
69. Iqbal S, Goldman B, Lenz HJ, et al. Southwest Oncogy Group study S0413; a phase 2 trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011;published online; doi:10.1093/annonc/mdr021
70. Baselga J, Gelmon KA, Verma S, et al. Phase 2 trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44
71. Kiewe P, Hasmuller S, Kahllert S, et al. Phase 1 trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91 (Pubitemid 43837355)
72. Induction chemotherapy with nimotuzumab in locally advanced head and neck squamous cell carcinoma (HNSCC)-a phase 2 trial. www. clinicaltrials.gov #NCT00910117
73. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
74. Vogel CL, Burris HA, LImentani S, et al. A phase 2 study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients with HER2 positive MBC: final results. J Clinic Oncol 2009;27(15s); abstract 1017
75. Rixe O, Franco S, Yardley D, et al. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2009;64:1139-48
76. Burstein HJ, Sun Y, Tan AR, et al. Neratinib (HKI-272) an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. J Clin Oncol 2010;28:1301-7
77. Hickish D, Wheatley N, Carey S, et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. ASCO Annual Meeting 2009. J Clin Oncol 2009:15(Suppl):abstract 1023
78. Hayashi A, Tamura T, Yusa T, et al. A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-over-expressing cancer [abstract 3143]. Presented at the San Antonio Breast Cancer Symposium, Dec 10-14, 2008, San Antonio, TX
79. Wong TW, Lee FY, Yu C, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/ HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12:6186-93 (Pubitemid 44703785)
80. Torres M, Raju U, Molkentine D, et al. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs 2011;29:554-61